These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies. Magy L; Mathis S; Vallat JM Curr Opin Crit Care; 2011 Apr; 17(2):101-5. PubMed ID: 21157311 [TBL] [Abstract][Full Text] [Related]
45. [Present status of high-dose intravenous immunoglobulin therapy and the future prospects ]. Kawasugi K Nihon Rinsho Meneki Gakkai Kaishi; 2003 Jun; 26(3):87-95. PubMed ID: 12868126 [No Abstract] [Full Text] [Related]
46. Demyelinating polyneuropathy associated with chronic inactive hepatitis B infection. Babatin MA; AlJohani A BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33766960 [TBL] [Abstract][Full Text] [Related]
47. Immunoglobulin for concurrent Guillain-Barré and immune thrombocytopenic purpura. Zeidman LA; Fahey CD; Grinblatt DL; Harsanyi K Pediatr Neurol; 2006 Jan; 34(1):60-2. PubMed ID: 16376282 [TBL] [Abstract][Full Text] [Related]
48. Novel pathomechanisms in inflammatory neuropathies. Schafflick D; Kieseier BC; Wiendl H; Meyer Zu Horste G J Neuroinflammation; 2017 Nov; 14(1):232. PubMed ID: 29179723 [TBL] [Abstract][Full Text] [Related]
49. [Acute and chronic inflammatory neuropathies--therapy]. Köller H; Kieseier BC; Jander S; Hartung HP Dtsch Med Wochenschr; 2003 Jun; 128(25-26):1405-7. PubMed ID: 12813675 [No Abstract] [Full Text] [Related]
50. Intravenouse immunoglobuline in dysautonomia. Gavrilova N; Kamaeva E; Ignatova M; Ryabkova V; Lukashenko M; Soprun L; Churilov LP; Shoenfeld Y Clin Immunol; 2022 Jul; 240():109039. PubMed ID: 35569781 [TBL] [Abstract][Full Text] [Related]
51. Clinical and pathophysiological implications of autoantibodies in autoimmune neuropathies. Collet R; Caballero-Ávila M; Querol L Rev Neurol (Paris); 2023 Oct; 179(8):831-843. PubMed ID: 36907709 [TBL] [Abstract][Full Text] [Related]
52. What is new in 2015 in dysimmune neuropathies? Kuntzer T Rev Neurol (Paris); 2016 Dec; 172(12):779-784. PubMed ID: 27866728 [TBL] [Abstract][Full Text] [Related]
55. Current treatment of neuromuscular diseases. Kokontis L; Gutmann L Arch Neurol; 2000 Jul; 57(7):939-43. PubMed ID: 10891975 [No Abstract] [Full Text] [Related]
56. Inflammatory neuropathies--pathogenesis and the role of intravenous immune globulin. van der Meché FG; van Doorn PA; Jacobs BC J Clin Immunol; 1995 Nov; 15(6 Suppl):63S-69S. PubMed ID: 8613494 [TBL] [Abstract][Full Text] [Related]
57. Advances in the use of IVIg in neurological disorders. Hughes R J Neurol; 2008 Jul; 255 Suppl 3():1-2. PubMed ID: 18685918 [No Abstract] [Full Text] [Related]
59. Guillain-Barré syndrome (demyelinating) six weeks after bariatric surgery: A case report and literature review. Ishaque N; Khealani BA; Shariff AH; Wasay M Obes Res Clin Pract; 2015; 9(4):416-9. PubMed ID: 25765350 [TBL] [Abstract][Full Text] [Related]